Curaleaf’s Bid for Aurora Is Trading Like a Deal That Won’t Close

Why Curaleaf Wants Aurora — and Why the Market Doubts It

The headline terms look straightforward. Curaleaf is offering 0.3463 subordinate voting shares plus $0.75 cash per Aurora share — $4.00 per share, a 45% premium to Aurora’s unaffected 30-day VWAP of US$2.75, capped at US$5.00.

Rolando argues the revealing calculation starts after that. Aurora holds roughly $109 million in cash against a $253 million purchase price. Net it out and Curaleaf is paying about $144 million for the operating business — roughly 0.7× revenue for a company with EU-GMP-certified indoor production and established medical operations across Germany, Poland, the UK and Australia.

So how does a 45% premium still buy a company cheaply?

The answer starts years before the bid

Aurora was once the industry’s great consolidator — Pedanios, a hostile run at CanniMed, C$3.2 billion for MedReleaf. By late 2018 it was worth roughly US$5.7 billion and building toward 625,000 kilograms of annual capacity.

Then Canada’s recreational market failed to absorb what the industry had built for it.

What followed was roughly C$5 billion in impairments since fiscal 2021 and more than C$480 million in negative operating cash flow. What survived is a much smaller company with no term debt and an international medical business that now drives almost all revenue.

Aurora had a timing problem: it overbuilt before demand existed, then cut capacity just as international medical demand began accelerating. The consolidator became the target.

Why Aurora? Because the alternatives don’t work

Boris Jordan has said he wants genetics and indoor EU-GMP cultivation. Rolando adds two constraints Jordan hasn’t said out loud: Curaleaf needs a target it can afford, and one without a large shareholder able to block the deal.

Run the alternatives through all four filters and they disappear:

That leaves Aurora with an unusual combination: certified indoor capacity, European distribution, a clean balance sheet, an affordable valuation, and no shareholder above about 2%.

Aurora is essentially the only public company that passes all four tests — which strengthens Aurora’s hand, because Curaleaf has no substitute.

What the market is actually saying

Analysts read the 8% discount as evidence the deal is nearing completion. Rolando reads it the other way: a spread that wide can signal doubt the transaction closes on its current terms at all.

One reason is a condition Curaleaf imposed on itself. Canadian takeover rules require more than 50% of independent shares. Curaleaf voluntarily set its threshold at 66⅔% on a fully diluted basis — a much harder number in Aurora’s fragmented, largely retail shareholder base.

And a second fight has opened. Curaleaf has asked the Alberta Securities Commission to intervene in Aurora’s ATM program after the company issued roughly 2.81 million shares at an average of US$3.04 since Curaleaf’s June approach — about US$11 million in additional acquisition cost. Rolando questions whether those issuances amount to a meaningful takeover defense. But leaving the program running has handed Curaleaf another argument to use against the board.

The clock runs to Dec. 1. The question is whether Curaleaf can persuade two-thirds of Aurora’s shareholders — and what happens if it can’t.

Four stories. One question: who gets the money?

Capital is returning to cannabis. Getting your hands on it is a different matter.

Institutional investors are looking again. For years institutions treated cannabis as almost uninvestable. Village Farms SVP of Corporate Affairs and IR Sam Gibbons tells IgniteIt that household-name institutions are starting to return — screening for growth, profitability, footprint, compliance and disciplined capital allocation. Read the exclusive interview →

Virginia will hand out 350 licenses. That’s the easy part. The proposed adult-use framework uses lotteries to broaden participation and cuts some upfront capital requirements for impact applicants. Winners still have to secure real estate, build facilities, clear local approvals and actually open. Read: Virginia’s cannabis lottery →

Who can still borrow? Cannabis banker Peter Su walks through what lenders want to see, who’s still getting funded, and where operators are getting into trouble. Read: the cash-flow test →

And what it looks like without the money. Veterans Holdings hit No. 130 on the 2026 Inc. 5000 on 2,342% three-year growth, its second straight year near the top. Founder and CEO Jason Ambrosino scaled the New York manufacturer from under six figures toward nearly $20 million in expected revenue while retaining ownership, limiting debt, buying used equipment and building expertise in-house. Read: how Veterans Holdings grew 2,342% →